1. Home
  2. N-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide

Contact Angene

Tel: +852 8191 6999

Email: [email protected]

Brc1cnc(nc1)C
Pyrimidine, 5-bromo-2-methyl-
CCCP1(=O)OP(=O)(CCC)OP(=O)(O1)CCC
1,3,5,2,4,6-Trioxatriphosphorinane, 2,4,6-tripropyl-, 2,4,6-trioxide
CC1(C)OB(OC1(C)C)B1OC(C(O1)(C)C)(C)C
2,2'-Bi-1,3,2-dioxaborolane, 4,4,4',4',5,5,5',5'-octamethyl-
O=C(C=Cc1ccccc1)C=Cc1ccccc1.O=C(C=Cc1ccccc1)C=Cc1ccccc1.O=C(C=Cc1ccccc1)C=Cc1ccccc1.[Pd].[Pd]
Tris(dibenzylideneacetone)dipalladium
C1CCC(CC1)P(C1CCCCC1)C1CCCCC1.Cc1cc(C)c(c(c1)C)N1CCN(C1=[Ru](=Cc1ccccc1)(Cl)Cl)c1c(C)cc(cc1C)C
Ruthenium,[1,3-bis(2,4,6-trimethylphenyl)-2-imidazolidinylidene]dichloro(phenylmethylene)(tricyclohexylphosphine)-, (SP-5-41)-

N-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide

O=C(C1CC1)Nc1cccc(c1)Nc1ncnc(c1)Nc1cccc(c1)C(F)(F)F Request for Quotation
Chemical Name: N-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide
CAS Number: 879127-07-8
Product Number: AG008CAI(AGN-PC-0MTEI1)
Synonyms:
MDL No:
Molecular Formula: C21H18F3N5O
Molecular Weight: 413.3957

Identification/Properties

Computed Properties
Molecular Weight:
413.404g/mol
XLogP3:
4.5
Hydrogen Bond Donor Count:
3
Hydrogen Bond Acceptor Count:
8
Rotatable Bond Count:
6
Exact Mass:
413.146g/mol
Monoisotopic Mass:
413.146g/mol
Topological Polar Surface Area:
78.9A^2
Heavy Atom Count:
30
Formal Charge:
0
Complexity:
586
Isotope Atom Count:
0
Defined Atom Stereocenter Count:
0
Undefined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
Covalently-Bonded Unit Count:
1
Compound Is Canonicalized:
Yes

Safety Information

NMR Spectrum

Other Analytical Data

Request for Quotation

Customer Feedback

Chemical Structure


EGFR inhibitors, also known as epidermal growth factor receptor inhibitors, play a crucial role in chemical synthesis by selectively targeting and inhibiting the activity of the epidermal growth factor receptor. This inhibition of EGFR can lead to the disruption of cellular signaling pathways involved in cell growth, proliferation, and survival.In chemical synthesis, EGFR inhibitors are particularly valuable in the development of novel pharmaceutical compounds and drug candidates. By modulating EGFR activity, these inhibitors can potentially alter cellular responses and influence various biological processes. This targeted approach offers a precise way to control specific pathways that may be involved in disease progression, making EGFR inhibitors versatile tools in medicinal chemistry research.Furthermore, EGFR inhibitors can be utilized in the synthesis of complex organic molecules through medicinal chemistry strategies. By integrating these inhibitors into the design of drug-like compounds, researchers can explore structure-activity relationships and optimize the pharmacological properties of potential drug candidates. This approach enables the rational design and synthesis of compounds that exhibit enhanced efficacy and selectivity, paving the way for the development of innovative therapeutic agents with improved clinical outcomes.